Navigation Links
Preferable treatment for MS found in allogenic bone marrow stem cells
Date:12/18/2013

Putnam Valley, NY. (Dec. 18, 2013) Multiple sclerosis (MS), an inflammatory autoimmune disease affecting more than one million people worldwide, is caused by an immune reaction to myelin proteins, the proteins that help form the myelin insulating substance around nerves. Demyelination and MS are a consequence of this immune reaction. Bone marrow mesenchymal stem cells (MSCs) have been considered as an important source for cell therapy for autoimmune diseases such as MS because of their immunosuppressive properties.

Now, a research team in Brazil has compared MSCs isolated from MS patients and from healthy donors to determine if the MSCs from MS patients are normal or defective. The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1131.

"The ability of MSCs to modulate the immune response suggests a possible role of these cells in tolerance induction in patients with autoimmune diseases, and also supports the rationale for MSC application in the treatment of MS," said study corresponding author Dr. Gislane Lelis Vilela de Oliveira of the Center for Cell-Based Research at the University of Sao Paulo. "We found that MS patient-derived MSCs present higher senescence, or biological aging, and decreased expression of important immune system markers as well as a different transcriptional profile when compared to their healthy counterparts."

The researchers suggested that further clinical studies should be conducted using transplanted allogenic (other-donated) MSCs derived from healthy donors to determine if the MSCs have a therapeutic effect over transplanted autologous (self-donated) MSCs from patients.

"Several reports have shown that bone marrow-derived MSCs are able to modulate innate and adaptive immunity cell responses and induce tolerance, thus supporting the rationale for their application in treating autoimmune diseases, " said the researchers.

They also noted that studies have shown that transplanted MSCs migrate to demyelinated areas as well as induce generation and expansion of regulatory T cells, important in immunity.

"We found that the transcriptional profile of patient MSCs after transplantation was closer to that of their pre-transplant MSC samples than those from their healthy counterparts, suggesting that treatment with patient self-donated MSCs does not reverse the alterations we observed in MSCs from MS patients," they concluded.

The researchers further noted that their results might not be representative of "typical" MS patients because their study included only patients who were refractory to conventional treatments.

"This study highlights one of the potential problems with autologous stem cell transplants" said Dr. Paul R. Sanberg, distinguished professor at the Center of Excellence for Aging and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL. "Autologous cells are frequently affected by the disease etiology thus reducing their ability to be effective, meaning that allogenic transplants maybe preferable to maximize their potential benefit if other concerns such as rejection can be overcome."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Packaging insulin into a pill-friendly form for diabetes treatment
2. Physicians awarded $4 million to study effects of fertility treatments and obstetric care
3. U-M tinnitus discovery opens door to possible new treatment avenues
4. Wayne State discovers potential treatment for skin and corneal wound healing in diabetics
5. New gene therapy proves promising as hemophilia treatment
6. Picturing pain could help unlock its mysteries and lead to better treatments
7. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
8. Targeted treatment can significantly reduce relapse in children with AML leukemia
9. Columbias 2013 Horwitz Prize awarded for discoveries that could lead to new Alzheimers treatments
10. MassBiologics receives orphan drug status from FDA for hepatitis C treatment
11. New compound for slowing the aging process can lead to novel treatments for brain diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... Mass. , March 22, 2017   Boston ... next-generation cancer therapeutics designed to target cancer stemness pathways, ... Patricia S. Andrews as Chief Executive Officer, effective ... succeed Chiang J. Li , M.D., FACP, who ... ten years ago. Under his leadership, Boston Biomedical has ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone Partners, is ... by Hunt Scanlon Media. , Hunt Scanlon Media is one of the ... global news source in the human capital sector. , “It is a great honor ...
Breaking Biology Technology: